Literature DB >> 28066651

Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance.

Zachary A Yochum1, Mark A Socinski2, Timothy F Burns1.   

Abstract

Entities:  

Year:  2016        PMID： 28066651      PMCID： PMC5179406          DOI： 10.21037/jtd.2016.11.59

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

Review 1.  TWISTing an embryonic transcription factor into an oncoprotein.

Authors:  S Ansieau; A-P Morel; G Hinkal; J Bastid; A Puisieux
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

Review 2.  Molecular mechanisms of epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Jian Xu; Rik Derynck
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

Review 3.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Authors:  Naoko Takebe; Lucio Miele; Pamela Jo Harris; Woondong Jeong; Hideaki Bando; Michael Kahn; Sherry X Yang; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

4.  SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer.

Authors:  A Emre Sayan; Thomas R Griffiths; Raj Pal; Gareth J Browne; Andrew Ruddick; Tamer Yagci; Richard Edwards; Nick J Mayer; Hasan Qazi; Sandeep Goyal; Serena Fernandez; Kees Straatman; George D D Jones; Karen J Bowman; Alexandra Colquhoun; J Kilian Mellon; Marina Kriajevska; Eugene Tulchinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

Review 5.  Oncogenic roles of EMT-inducing transcription factors.

Authors:  Alain Puisieux; Thomas Brabletz; Julie Caramel
Journal:  Nat Cell Biol       Date:  2014-06       Impact factor: 28.824

6.  Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.

Authors:  Timothy F Burns; Irina Dobromilskaya; Sara C Murphy; Rajendra P Gajula; Saravanan Thiyagarajan; Sarah N H Chatley; Khaled Aziz; Yoon-Jae Cho; Phuoc T Tran; Charles M Rudin
Journal:  Mol Cancer Res       Date:  2013-01-30       Impact factor: 5.852

7.  Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition.

Authors:  H-O Jin; S-E Hong; S-H Woo; J-H Lee; T-B Choe; E-K Kim; W-C Noh; J-K Lee; S-I Hong; J-I Kim; I-C Park
Journal:  Cell Death Dis       Date:  2012-06-07       Impact factor: 8.469

Review 8.  The emerging role of Twist proteins in hematopoietic cells and hematological malignancies.

Authors:  N Merindol; A Riquet; V Szablewski; J-F Eliaou; A Puisieux; N Bonnefoy
Journal:  Blood Cancer J       Date:  2014-04-25       Impact factor: 11.037

Review 9.  EMT or EMT-Promoting Transcription Factors, Where to Focus the Light?

Authors:  Stéphane Ansieau; Guillaume Collin; Louise Hill
Journal:  Front Oncol       Date:  2014-12-16       Impact factor: 6.244

10.  A genetic cell context-dependent role for ZEB1 in lung cancer.

Authors:  Ting Zhang; Lixia Guo; Chad J Creighton; Qiang Lu; Don L Gibbons; Eunhee S Yi; Bo Deng; Julian R Molina; Zhifu Sun; Ping Yang; Yanan Yang
Journal:  Nat Commun       Date:  2016-07-26       Impact factor: 14.919
View more
  6 in total

Review 1.  The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.

Authors:  Yating Chen; Wenjie Guo; Junsheng Fan; Yuqing Chen; Xiaoli Zhang; Xin Chen; Peng Luo
Journal:  Cancer Manag Res       Date:  2017-12-07       Impact factor: 3.989

2.  Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.

Authors:  Zachary A Yochum; Jessica Cades; Hailun Wang; Suman Chatterjee; Brian W Simons; James P O'Brien; Susheel K Khetarpal; Ghali Lemtiri-Chlieh; Kayla V Myers; Eric H-B Huang; Charles M Rudin; Phuoc T Tran; Timothy F Burns
Journal:  Oncogene       Date:  2018-08-31       Impact factor: 9.867

3.  The effects of growth hormone on therapy resistance in cancer.

Authors:  Reetobrata Basu; John J Kopchick
Journal:  Cancer Drug Resist       Date:  2019-09-19

4.  Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.

Authors:  Beatriz Andrea Otálora-Otálora; Daniel Alejandro Osuna-Garzón; Michael Steven Carvajal-Parra; Alejandra Cañas; Martín Montecino; Liliana López-Kleine; Adriana Rojas
Journal:  Biology (Basel)       Date:  2022-07-20

5.  Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases.

Authors:  Beatriz Andrea Otálora-Otálora; Mauro Florez; Liliana López-Kleine; Alejandra Canas Arboleda; Diana Marcela Grajales Urrego; Adriana Rojas
Journal:  Front Genet       Date:  2019-12-06       Impact factor: 4.599

6.  Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer.

Authors:  Hongye Zhang; Ruiyu Wang; Mingxia Wang; Judong Luo; Changmin Liu
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.